Xiaoling Ou
Impact in
-
- Lung Cancer Treatments and Mutations
- Ophthalmology top 5%
- Traumatic Ocular and Foreign Body Injuries
Papers in
-
- Lung Cancer Treatments and Mutations 9
- Gastric Cancer Management and Outcomes 2
-
- Fault Detection and Control Systems 3
- Co-authors
- Myung‐Ju Ahn (7 shared papers)Mireille Cantarini (7 shared papers)Byoung Chul Cho (4 shared papers)James Chih‐Hsin Yang (6 shared papers)Wu‐Chou Su (5 shared papers)Paul Frewer (5 shared papers)Dariusz M. Kowalski (4 shared papers)Lecia V. Sequist (5 shared papers)
- Journals
- Journal of Thoracic Oncology (2 papers)Annals of Oncology (2 papers)Neural Computing and Applications (1 paper)Clinical Cancer Research (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- United KingdomUnited StatesSouth Korea
In The Last Decade
Xiaoling Ou
16 papers receiving 608 citations
Xiaoling Ou's Hit Papers
Peers
Comparison fields: 5 of 65
- Pulmonary and Respiratory Medicine 368
- Ophthalmology 72
- Oncology 218
- Hepatology 45
- Cancer Research 62
Countries citing papers authored by Xiaoling Ou
This map shows the geographic impact of Xiaoling Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Ou more than expected).
Fields of papers citing papers by Xiaoling Ou
This network shows the impact of papers produced by Xiaoling Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Ou. The network helps show where Xiaoling Ou may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaoling Ou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Hit paper breakdown → | 2020 | 306 |
| 2 | 2022 | 101 | |
| 3 | 2011 | 55 | |
| 4 | 2022 | 51 | |
| 5 | 2011 | 41 | |
| 6 | 2017 | 17 | |
| 7 | 2022 | 13 | |
| 8 | 2021 | 9 | |
| 9 | 2007 | 7 | |
| 10 | 2021 | 5 | |
| 11 | 2007 | 4 | |
| 12 | A Neural Network Model for Urban Traffic Volumes Compression | 2003 | 3 |
| 13 | 2004 | 2 | |
| 14 | 2019 | 1 | |
| 15 | 2019 | 1 | |
| 16 | 2020 | 1 | |
| 17 | 2024 | 0 |
About Xiaoling Ou
Xiaoling Ou is a scholar working on Pulmonary and Respiratory Medicine, Control and Systems Engineering, Molecular Biology, Genetics and Oncology, having authored 17 papers that have together received 617 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Fault Detection and Control Systems (3 papers), Spectroscopy and Chemometric Analyses (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Gaussian Processes and Bayesian Inference (2 papers), Gastric Cancer Management and Outcomes (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (368 citations), Ophthalmology (72 citations), Oncology (218 citations), Hepatology (45 citations) and Cancer Research (62 citations). Xiaoling Ou has collaborated with scholars based in United Kingdom, United States and South Korea. Frequent co-authors include Myung‐Ju Ahn, Mireille Cantarini, Byoung Chul Cho, James Chih‐Hsin Yang, Wu‐Chou Su, Paul Frewer, Dariusz M. Kowalski, Lecia V. Sequist, Jong Seok Lee and Ji‐Youn Han. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Neural Computing and Applications, Clinical Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.